IL6R and systemic-onset juvenile idiopathic arthritis: Similarly to IL-1Ra, tocilizumab, an IL-6R antibody, has demonstrated efficacy in the treatment of systemic juvenile idiopathic arthritis (sJIA), severe rheumatoid arthritis, multicentric Castleman’s disease, and CART therapy-induced CRS.58,532–535 In addition, IFN-γ is a potential target for CS control.